# CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation

> **NCT02910752** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** CLAM+PBSC

## Key facts

- **NCT ID:** NCT02910752
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2016-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910752, "CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02910752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*